858                                 Laws of Maryland                        [Ch. 422

(b) If its labeling or packaging fails to conform with the re-
quirements of Section 191A of this subheading.

(2)    If in package form, unless it bears a label containing the
name and place of business of the manufacturer, packer, or distrib-
utor.

(3)    If any word, statement, or other information required by or
under authority of this subheading to appear on the label or labeling
is not prominently placed thereon with conspicuousness (as com-
pared with other words, statements, designs or devices, in the labeling)
and in terms to render it likely to be read and understood by the
ordinary individual under customary conditions of purchase and use.

(4) If it is for use by man and contains any quantity of the
narcotic or hypnotic substance alpha-eucaine, barbituric acid, beta-
eucaine, bromal, cannabis, carbromal, chloral, coca leaves, cocaine,
codeine, heroin, marijuana, morphine, opium, paraldehyde, peyote,
or sulphonmethane, or any chemical derivative of such substance,
which derivative, after investigation, has been found to be and
designated as, habit forming, by regulations issued by the Secretary
under this subheading, or by regulations issued pursuant to Section
502 352 (d) of the Federal Act, unless its label bears the name and
quantity or proportion of the substance or derivative and in jux-
taposition therewith the statement "Warning—May be habit form-
ing."

(5)    If it is a drug, unless (a) its label bears, to the exclusion
of any other non-proprietary name (except the applicable systematic
chemical name or the chemical formula), (i) the established name
(as defined in subparagraph (2)) of the drug, if such there be,
and (ii) in case it is fabricated from two or more ingredients, the
established name and quantity of each active ingredient, including
the kind and quantity or proportion of any alcohol and also including,
whether active or not, the established name and quantity or pro-
portion of any bromides, ether, chloroform, acetanilid, acetphene-
tidin, amidopyrine, antipyrine, atropine, hyoscine, hyoscyamine,
arsenic, digitalis, digitalis glucosides, mercury, ouabain, strophan-
thin, strychnine, thyroid, or any derivative or preparation of any such
substances, contained therein: provided, that the requirement for
stating the quantity of the active ingredients, other than the quantity
of those specifically named in this subsection, shall apply only to
prescription drugs; and (b) for any prescription drug the established
name of such drug or ingredient, as the case may be, on such
label (and on any labeling on which a name for such drug or in-
gredient is used) is printed prominently and in type at least half as
large as that used thereon for any proprietary name or designation
for such drug or ingredient; provided, however, that to the extent
that compliance with the requirements of clause (a) (ii) or clause
(b) of this subparagraph is impracticable, exemptions shall be
allowed under regulations promulgated by the Secretary, or under
the Federal Act.

(6)    As used in paragraph (5) of this section the term "established
name," with respect to a drug or ingredient thereof, means (a) the
applicable official name designated pursuant to Section 508 358 of the
Federal Act, or (b) if there is no such name and the drug or in-
gredient is an article recognized in an official compendium, then
the official title thereof in the compendium or (c) if neither clause